Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

BACKGROUND: Vildagliptin and pioglitazone/rosiglitazone are emerging Oral Hypoglycemic Agents (OHAs) which are used to treat patients suffering from Type 2 Diabetes Mellitus (T2DM). In this analysis, we aimed to systematically compare the adverse drug events which were observed with the use of vilda...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMC Pharmacol Toxicol
Hlavní autoři: Bundhun, Pravesh Kumar, Janoo, Girish, Teeluck, Abhishek Rishikesh, Huang, Feng
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2017
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5651605/
https://ncbi.nlm.nih.gov/pubmed/29058622
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40360-017-0175-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky